Conversion to once-daily tacrolimus results in increased p38MAPK phosphorylation in T lymphocytes of kidney transplant recipients

Therapeutic Drug Monitoring

Volumn 38, Issue 2, 2016, Pages 280-284

  Kannegieter, Nynke M ^a   Shuker, Nauras ^a   Vafadari, Ramin ^a   Weimar, Willem ^a   Hesselink, Dennis A ^a   Baan, Carla C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Oncedaily tacrolimus; P38MAPK; Pharmacodynamic monitoring; Phospho specific flow cytometry; Transplantation

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; MYCOPHENOLATE MOFETIL; PREDNISOLONE; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GRAFT RECIPIENT; HUMAN; IMMUNOASSAY; KIDNEY GRAFT; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; ADULT; AGED; BLOOD; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG MONITORING; FEMALE; GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; PROCEDURES; T LYMPHOCYTE; YOUNG ADULT;

ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PREDNISOLONE; T-LYMPHOCYTES; TACROLIMUS; TRANSPLANT RECIPIENTS; YOUNG ADULT;

EID: 84947997703     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000264     Document Type: Article

References (18)

1. Sommerer C, Giese T, Meuer S, et al. Pharmacodynamic monitoring of calcineurin inhibitor therapy: is there a clinical benefit? Nephrol Dial Transplant. 2009;24:21-27.
2. van Rossum HH, de Fijter JW, van Pelt J. Pharmacodynamic monitoring of calcineurin inhibition therapy: principles, performance, and perspectives. Ther Drug Monit. 2010;32:3-10.
3. Klupp J, Holt DW, van Gelder T. How pharmacokinetic and pharmaco-dynamic drug monitoring can improve outcome in solid organ transplant recipients. Transpl Immunol. 2002;9:211-214.
4. Vafadari R, Hesselink DA, Cadogan MM, et al. Inhibitory effect of tacrolimus on p38 mitogen-activated protein kinase signaling in kidney transplant recipients measured by whole-blood phosphospecific flow cy-tometry. Transplantation. 2012;93:1245-1251.
5. Matsuda S, Koyasu S. Regulation of MAPK signaling pathways through Immunophilin-ligand Complex. Curr Top Med Chem. 2003; 3:1358-1367.
6. Barraclough KA, Isbel NM, Johnson DW, et al. Once-versus twice-daily tacrolimus. Drugs. 2011;71:1561-1577.
7. Shuker N, Cadogan M, van Gelder T, et al. Conversion from twice-daily to once-daily tacrolimus does not reduce intra-patient variability in tacrolimus exposure. Ther Drug Monit. 2015;37:262-269.
8. Irish JM, Hovland R, Krutzik PO, et al. Single cell profiling of potentiated phospho-protein networks in Cancer cells. Cell. 2004; 118:217-228.
9. Baan C, Bouvy A, Vafadari R, et al. Phospho-specific flow cytometry for pharmacodynamic monitoring of immunosuppressive therapy in transplantation. Transplant Res. 2012;1:2047-1440.
10. Krämer BK, Charpentier B, Bäckman L, et al. Tacrolimus once daily (AD-VAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am J Transplant. 2010;10:2632-2643.
11. Albano L, Banas B, Klempnauer JL, et al. OSAKA trial: a randomized, Controlled trial comparing tacrolimus QD and BD in kidney transplantation. Transplantation. 2013;96:897-903.
12. van Hooff JP, Alloway RR, Trunecka P, et al. Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studies. Clin Transplant. 2011;25:E1-E12.
13. Tsuchiya T, Ishida H, Tanabe T, et al. Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus. Transplantation. 2013;96:198-204.
14. Hougardy J, Broeders N, Kianda M, et al. Conversion from prograf to advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. Transplantation. 2011;91:566-569.
15. Wu M, Cheng C, Chen C, et al. Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients. Transplantation. 2011;92:648-652.
16. Lapeyraque A, Kassir N, Théorêt Y, et al. Conversion from twice-to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study. Pediatr Nephrol. 2014;29:1081-1088.
17. Cook R, Wu CC, Kang YJ, et al. The role of the p38 pathway in adaptive immunity. Cell Mol Immunol. 2007;4:253-259.
18. Heeger PS. T-cell allorecognition and transplant rejection: a summary and update. Am J Transplant. 2003;3:525-533.